|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Trading: BUY @ $0.135
Signal Strength: MEDIUM
Volatility indicators highlight potential moves of a stock which can either move sharply in the updwards or downwards direction. This indicator allows stocks to be compared on a level playing field to highlight high and low volatility. Normally, falling markets are more likely to be volatile than a rising markets due to the emotion that gets tied to trading. Use volatility indicators in conjunction with other indicators to reduce exposure to false moves.
Bionomics (ASX:BNO) UIX index implies that the downside risk of the current trading price is high. Currently, the UIX is 7.946.
A technical indicator that measures downside risk in terms of both depth and duration of price declines. The Ulcer Index (UI) increases in value as the price moves farther away from a recent high and falls as the price rises to new highs. The indicator is usually calculated over 14 days with the UI showing the percentage drawdown a trader can expect from the high over that period. The greater the value of the UI the longer it takes for a stock to get back to the former high.
Calculation: Ulcer Index:
1) Percentage Drawdown = [(Close - 14-period High Close)/14-period High Close] x 100;
2) Squared Average = (14-period Sum of Percentage Drawdown Squared)/14;
3) Ulcer Index = Square Root of Squared Average;
PROFILE: Bionomics (BNO.AX)
Stock Exchange: ASX
Ticker Codes: | BNO.AX | ASX:BNO |
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company's product pipeline includes BNC210, a novel and proprietary negative allosteric modulator, which is in Phase II clinical trial for the treatment of generalized anxiety disorder, as well as is in the initiation of a Phase II clinical trial in patients with post-traumatic stress disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. It also offers contract research services. The company has partnerships with Merck & Co., Inc.; Cancer Therapeutics Cooperative Research Centre; Genmab A/S; Laboratory Corporation of America (LabCorp); Athena Diagnostics; and Genetic Technologies Limited. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.
|GNG GR Engineering Services||0.95||9.8||41,600||7.95||BEARISH|
|WBC Westpac Banking Corporation||27.75||9.2||24,404,464||5.77||BEARISH|
|ALK Alkane Exploration||0.24||9.1||1,447,163||8.27||BEARISH|
|AHG Advance Healthcare||2.55||9||1,585,387||6.2||BEARISH|
|OVH Onevue Holdings||0.49||8.9||426,122||7.89||BEARISH|
|RHC Ramsay Health Care||69.58||7.3||1,172,273||9.74||BEARISH|
|AYS Amaysim Australia||0.76||7||283,622||7.58||BEARISH|
|CBA Commonwealth Bank||77.4||6.3||9,829,411||7.04||BEARISH|